Cargando…

PB2157: TREATMENT WITH DIPHENYLENEIODONIUM CHLORIDE EXHIBITS CELL GROWTH INHIBITORY EFFECTS ON AGGRESSIVE LYMPHOMA CELLS

Detalles Bibliográficos
Autores principales:	Haingartner, S., Jantscher, S., Pansy, K., Szmyra, M., Neumeister, P., Greinix, H., Deutsch, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431501/ http://dx.doi.org/10.1097/01.HS9.0000851456.75823.7d

Ejemplares similares

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB2157: AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY
por: Karimova, Ekaterina, et al.
Publicado: (2023)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity
por: Pandey, Manitosh, et al.
Publicado: (2017)

Efficacy of Diphenyleneiodonium Chloride (DPIC) Against Diverse Plant Pathogens
por: Jung, Boknam, et al.
Publicado: (2019)

Targeting the Microenvironment for Treating Multiple Myeloma
por: Neumeister, Peter, et al.
Publicado: (2022)

PB2137: INFLUENCE OF PREVIOUS RADIOTHERAPY ON THE EFFECT OF CART CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA
por: Shaomei, F.
Publicado: (2022)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

Author Correction: Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity
por: Pandey, Manitosh, et al.
Publicado: (2018)

PB2332: CLINICAL CHARACTERISTICS AND OUTCOMES OF HIV-ASSOCIATED AGGRESSIVE B-CELL NHL IN CHINA
por: Wang, Chaoyu, et al.
Publicado: (2023)

Inhibition of NADPH Oxidases Activity by Diphenyleneiodonium Chloride as a Mechanism of Senescence Induction in Human Cancer Cells
por: Piszczatowska, Katarzyna, et al.
Publicado: (2020)

PB2123: MANAGEMENT OF PATIENTS WITH CONCOMITANT LIVER CIRRHOSIS AND AGGRESSIVE LYMPHOMA – A LITERATURE REVIEW
por: Jelicic, J., et al.
Publicado: (2022)

PB2268: PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA
por: Zhang, Xin, et al.
Publicado: (2023)

Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas
por: Uhl, Barbara, et al.
Publicado: (2022)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB1829: QUERCETIN EXHIBITS ANTI-LEUKEMIA EFFECTS VIA REGULATION OF METABOLIC REPROGRAMMING
por: Zhang, Jing, et al.
Publicado: (2023)

Adherence of Trichomonas vaginalis to SiHa Cells is Inhibited by Diphenyleneiodonium
por: Kim, Yeeun, et al.
Publicado: (2020)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2382: EFFECTS OF ANTIFASCIN COMPOUNDS AGAINST LYMPHOMA CELLS IN VITRO
por: María Hurtado López, Ana, et al.
Publicado: (2023)

Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP)
por: Neubauer, Regina, et al.
Publicado: (2013)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

Lung specific homing of diphenyleneiodonium chloride improves pulmonary fibrosis by inhibiting macrophage M2 metabolic program
por: Wang, Huirui, et al.
Publicado: (2022)

Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
por: Pansy, Katrin, et al.
Publicado: (2021)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY
por: Bronstein, Yotam, et al.
Publicado: (2023)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
por: Valentin Hansen, Simone, et al.
Publicado: (2023)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2153: SURGICAL SPECIMENS OF INDOLENT AND AGGRESSIVE B-NHLS SHOW DIFFERENCES IN THEIR FLOW-CYTOMETRY PROFILE OF PLOIDY, PROLIFERATING FRACTION AND PROPORTION OF TUMOR-ASSOCIATED MYELOID AND T-CELL SUBSETS
por: Azoulay, D., et al.
Publicado: (2022)

Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival
por: Fechter, Karoline, et al.
Publicado: (2018)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2094: PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Charfi, M., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s32bv78h32fsfjkjc758u25ci7